Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Relapsing Multiple Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

TG Therapeutics Investigational Trial Site, Gdansk, Poland
TG Therapeutics Investigational Trial Site, Poznan, Poland

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE4

New Haven, United States · Washington D.C., United States

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE2

Boston, United States · Farmington Hills, United States

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Multiple Sclerosis · Multiple Sclerosis (MS) - Relapsing-remitting

Abroad (travel likely)RecruitingPHASE4

Chicago, United States

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Relapsing Multiple Sclerosis · Relapsing Remitting Multiple Sclerosis · Secondary Progressive Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE3

Palo Alto, United States · Aurora, United States